Patents by Inventor Zhuobing Zhang

Zhuobing Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Epidermal growth factor receptor antibody
    Patent number: 9644031
    Abstract: Provided are an improved EGFR antibody or a functional segment thereof, comprising an engineered heavy chain and light chain. Specifically, the antibody is an engineered whole human-source monoclonal antibody. Also provided is a method for manufacturing said whole human-source antibody and usage of the antibody in the manufacture of medicines used for the treatment of tumors.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: May 9, 2017
    Assignees: GENRIX (SHANGHAI) BIOPHARMACERTICAL CO., LTD., BIOEX THERAPEUTICS INC.
    Inventors: Jie Liu, Zhuobing Zhang, Jikuan Shan, Wei Suo
  • EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY
    Publication number: 20160017045
    Abstract: Provided are an improved EGFR antibody or a functional segment thereof, comprising an engineered heavy chain and light chain. Specifically, the antibody is an engineered whole human-source monoclonal antibody. Also provided is a method for manufacturing said whole human-source antibody and usage of the antibody in the manufacture of medicines used for the treatment of tumors.
    Type: Application
    Filed: October 6, 2015
    Publication date: January 21, 2016
    Applicants: BIOEX THERAPEUTICS INC., GENRIX (SHANGHAI) BIOPHARMACERTICAL CO., LTD.
    Inventors: Jie LIU, Zhuobing ZHANG, Jikuan SHAN, Wei SUO
  • Methods of treating cancer using a modified endostatin protein
    Patent number: 7470667
    Abstract: The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as a chemotherapy agent, or a radiotherapy agent.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: December 30, 2008
    Assignee: Medgenn (Hong Kong) Ltd
    Inventors: Yongzhang Luo, Zhuobing Zhang, Qingxin Lei, Yan Sun, Jinwan Wang
  • N-terminal modified recombinant human endostatin and its production
    Patent number: 7078485
    Abstract: The invention relates to endostatin protein, in particular, to N-terminal modified recombinant human endostatin (rhEndostatin) proteins which have an additional metal chelating peptide sequence at the N-terminal, the preparation thereof, and methods of modifying the rhEndostatin to improve its stability in vivo and in vitro, and its biological activity. The invention further related to the resulting N-terminal modified rhEndostatin protein, a pharmaceutical composition containing the same, and use of said modified rhEndostatin or its pharmaceutical composition in treating the angiogenesis-related diseases, especially angiogenesis-dependent tumors.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: July 18, 2006
    Assignee: Yantai Medgenn Ltd.
    Inventors: Yongzhang Luo, Bing Zhou, Zhuobing Zhang
  • Methods of treating cancer using a modified endostatin protein
    Publication number: 20060058232
    Abstract: The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as a chemotherapy agent, or a radiotherapy agent.
    Type: Application
    Filed: April 29, 2005
    Publication date: March 16, 2006
    Inventors: Yongzhang Luo, Zhuobing Zhang, Qingxin Lei
  • N-terminal modified recombinant human endostatin and its production
    Publication number: 20040110671
    Abstract: The invention relates to endostatin, protein, in particular, to N-terminal modified recombinant human endostatin (rhEndostatin) proteins which have an additional metal chelating peptide sequence at the N-terminal, the preparation thereof, and methods of modifying the rhEndostatin to improve its stability in vivo and in vitro, and its biological activity. The invention further related to the resulting N-terminal modified rhEndostatin protein, a pharmaceutical composition containing the same, and use of said modified rhEndostatin or its pharmaceutical composition in treating the angiogenesis-related diseases, especially angiogenesis-dependent tumors.
    Type: Application
    Filed: December 5, 2002
    Publication date: June 10, 2004
    Inventors: Yongzhang Luo, Bing Zhou, Zhuobing Zhang